ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.
ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs - guidance in brief
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
Hepatitis C - Annual Epidemiological Report 2016 [2014 data]
In 2014, 35 321 cases of hepatitis C were reported from 28 EU/EEA Member States, a crude rate of 8.8 cases per 100 000 population.
Hepatitis C - Annual Epidemiological Report for 2015
In 2015, 34 651 cases of hepatitis C were reported from 28 EU/EEA Member States, a crude rate of 8.6 per 100 000 population. Of the cases reported, 1.0% were classified as acute, 12.7% as chronic, 69.5% as ‘unknown’ and 16.8% were not classified.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.